



In Silico Prediction, Computational Physico Chemical Analysis in Gymnemic Acids

Dhanapal Indumathi*, Ramasamy Sujatha, and Palanisamy Shanmuga Sundaram

*Department of Nutrition and Dietetics, Thiruvalluvar Govt. Arts College, Rasipuram, Tamil Nadu, India..

Department of Nutrition and Dietetics, NKR Govt. Arts College for Women, Namakkal, Tamil Nadu, India.

Department of Chemistry, Thiruvalluvar Govt. Arts College, Rasipuram, Tamil Nadu, India.

Abstract: *Gymnema sylvestre* (Asclepiadaceae) also known as 'gurmar' or 'sugar destroyer' is a woody, climbing traditional medicinal herb which has many therapeutic applications in the Ayurvedic system of medicine. We present an overview of the most important databases with 2 gymnemic acid structural information about drugs and drug candidates, and of databases with relevant properties. Access to experimental data and numerical methods for selecting and utilizing these data is crucial for developing accurate predictive *in silico* models. Many interesting predictive methods for classifying the suitability of chemical compounds as potential drugs, as well as for predicting their physico-chemical and ADMET properties have been proposed in recent years. The gymnemic acids act as therapeutic agents and play vital roles in many therapeutic applications. Gymnemic acids are thought to be responsible for its anti-diabetic activity and are the major component of an extract shown to stimulate insulin release. It is also screened for bioavailability study, physicochemical study, drug likeness study, medicinal chemical analysis and target prediction. These methods are discussed, and some possible future directions in this rapidly developing field are also described. The commercial exploitation of this plant and its secondary metabolites are some of the major perspectives of this rare medicinal herb. The focus of the present study is to achieve the potential of therapeutic value of this herb its mechanism, and the action of their secondary metabolites.

Keywords: *G.sylvestre*, Gymnemic acids, bioavailability study, physicochemical study, Drug likeness study, medicinal chemical analysis, target prediction.

*Corresponding Author

Dhanapal Indumathi , Department of Nutrition and Dietetics,
Thiruvalluvar Govt. Arts College, Rasipuram, Tamil Nadu,
India. 8056335805.



Received On 6 August, 2021

Revised On 13 September, 2021

Accepted On 6 September, 2021

Published On 15 September, 2021

Funding This research did not receive any specific grant from any funding agencies in the public, commercial or not for profit sectors.

Citation Dhanapal Indumathi, Ramasamy Sujatha, and Palanisamy Shanmuga Sundaram , In Silico Prediction, Computational Physico Chemical Analysis in Gymnemic Acids.(2021).Int. J. Life Sci. Pharma Res.11(5), 145-150
<http://dx.doi.org/10.22376/ijpbs/lpr.2021.11.5.L145-150>

This article is under the CC BY- NC-ND Licence (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)



Copyright @ International Journal of Life Science and Pharma Research, available at www.ijlpr.com

Int J Life Sci Pharma Res., Volume 11., No 5 (September) 2021, pp 145-150

I. INTRODUCTION

G.sylvestre (Asclepiadaceae) a vulnerable species is a slow growing, perennial, medicinal woody climber found in central and peninsular India. Its leaves, called "Gurmar" in India, are well known for their sweet taste suppressing activity and are used for the treatment of diabetes mellitus¹ for over 2000 year, hence the name "Gurmar" meaning 'sugar destroying'. It is used in food additives against obesity. *G.sylvestre* is a woody, climbing herb indigenous to the tropical forests of central and southern India. The plant belongs to Kingdom Plantae with Division Angiospermae and Class Dicotyledoneae. *Gymnema* is native to south-Indian forests. It is a large tropical liana native to central and western India and can be also found in tropical Africa and in Australia. It is used for lowering serum cholesterol, triglycerides and blood glucose level (hypoglycemic or antihyperglycemic), hypolipidemic, weight loss, stomach ailments, constipation, water retention and liver diseases, either high or low blood pressure, tachycardia or arrhythmias, it is also used as aperitifs, purgative, in eye troubles, anti-inflammatory, smooth muscle relaxant, prevention of dental caries, cataract and as anticancer-cytotoxic agent. Its flowers, leaves, and fruits contain alkaloids, flavones, saponins, sapogenins, anthraquinones, hentri-acontane, pentatriacontane, α and β -chlorophylls, phytin, resins, d-quercitol, tartaric acid, formic acid, butyric acid, lupeol, β -amyrin related glycosides and stigmasterol with its main principle bioactive compounds viz². Gymnemic acids are isolated from the leaves of *G.sylvestre* (Asclepiadaceae), which is native to India and southern China. Gymnemic acids are glycosides of triterpene that suppress sweetness in humans³. After the leaves are chewed, the solutions that have been sweetened with sucrose taste like water. It is thought that gymnemic acid inhibits the binding of a sweet substance to the sweet receptor. Several gymnemic acid homologues with different acyl groups were purified from the leaves of *G.sylvestre* and their structures were determined. Interestingly, deletion of the acyl group diminishes the anti-sweet activity. It suppresses the sweetness of most of sweeteners, including intense artificial sweeteners such as aspartame and natural sweeteners such as thaumatin, a sweet protein. The herb is traditionally used for the treatment of diabetes in India and *Gymnema* extracts are sold in Japan for control of obesity⁴. It is a rich source of many bioactive compounds such as gymnemic acid (GA-I-X), quercitol, lupeol, stigmasterol, gymnemin, gymnemagenin, and gurmarin, which are mainly effective in the lowering of blood sugar. Gymnemic acid, the active ingredient of this plant, is extracted from leaves and is used widely as anti-diabetic⁵, anti-sweetner⁶ and anti-hypercholesterolemia⁷. It has stomachic, diuretic and cough suppressant property. The plant has been reported possessing antimicrobial⁸ and ethno-veterinary medicinal properties⁹. In addition, it possesses antimicrobial, hepatoprotective, and anti-saccharine activities. Hence, because of these properties, *G.sylvestre* is the most important for plant prospecting. Protein-protein interactions (PPIs) represent an essentially untapped source of potential targets for therapeutic interventions. The modulation of PPIs by low molecular weight chemical compounds, particularly by orally bioavailable molecules (i.e., the most convenient, safest and least expensive way to deliver drugs), would be very valuable in numerous disease indications¹⁰. The analysis of thousands of PPI inhibitors (iPPIs) (hits or molecules that went through optimization cycles) reported in several databases¹¹ indicated that these compounds have in general a high

lipophilicity (analysed via log P calculations) and a high molecular weight (MW), properties that are usually not favourable to the development of oral drugs (although there are numerous exceptions to these rules¹². While the current state of the art investigations performed on iPPIs have essentially focused on physicochemical properties¹³ in the present study, we move beyond these classical physicochemical properties (PC) to predict several Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) parameters using online servers and established commercial packages¹⁴. In order to outline iPPIs features, computations were carried out on eight datasets collected from several databases¹⁵. This study involves the *in silico* analysis of bioavailability, physicochemical, Drug likeness prediction, medicinal chemical analysis, target prediction in Gymnemic acids.

2. MATERIALS AND METHODS

2.1. Preparation of Extracts

Crude Sample *G.sylvestre* extract was prepared by Soxhlet extraction method. About 20gm of powdered *G.sylvestre* sample material was uniformly packed into a thimble and had extracted with 250ml of different solvents (Distilled water). The process of extraction had to be continued for 24 hours or till the solvent in the siphon tube of the extractor became colourless. After that the extract was taken in a beaker and kept on a hot plate and heated at 30-40 °C till all the solvent evaporated. Dried extract was kept in the refrigerator at 4 °C till future use. *G.sylvestre* (Retz.) R.Br.ex Sm. (*Periploca sylvestris* Retz.) ASCLEPIADACEAE. Identification and authentication of *G.sylvestre* was done by Dr. M. Palanisamy, Scientist, Botanical Survey of India, Southern Regional Centre, Coimbatore, Tamilnadu and the voucher number is BSIS/RC/5/23/2017/ Tech/ 530¹⁶.

2.1. Drug-Likeness Prediction

The OSIRIS Property Explorer uses chemical structures and calculates on-the-fly various drug-relevant properties whenever a structure is valid. Prediction results are valued and colour coded. Properties analysed are TPSA, calculation, molecular weight, fragment based drug-likeness, and drug score¹⁷.

2.2. ADMET Prediction

ADMET properties of a compound deal with its absorption, distribution, metabolism, excretion, and toxicity in and through the human body. ADMET, which constitutes the pharmacokinetic profile of a drug molecule, is very essential to evaluate its pharmacodynamics activities. Today, a lot of online tools and offline software programs are available which helps us in predicting this behaviour of the drug candidate. In this study, we have used the ADMET SAR prediction tool¹⁷.

3. RESULTS AND DISCUSSION

The interactions between protein ligands can be elucidated by molecular docking of ligands against the enzyme's active site¹⁸. In the area of drug discovery and development, this will pave the way for the discovery of novel phytomedicines. The GC-MS research compounds followed the Lipinski law of five. This law contains five sub-regulations, namely (1)

molecular weight (< 500), (2) log P (< +5.6), (3) hydrogen donor number (< 5), (4) hydrogen acceptor number (< 10) and (5) molar refractivity (40-130). The Lipinski rule of five is

3.1 Gymnemic acid




Fig 1: Chemical Bond of Gymnemic acid

3.2 Bioavailability Study

The coloured zone is the suitable physicochemical space for oral bioavailability

LPO (Lipophilicity): $-0.7 < \text{XLOGP3} < +5.0$

SIZE: $150\text{g/mol} < \text{MV} < 500\text{g/mol}$

POLAR (Polarity): $20 \text{ \AA}^2 < \text{TPSA} < 130 \text{ \AA}^2$

INSOLU (Insolubility): $0 < \text{Log S (ESCOL)} < 6$

INSATU (Insaturation): $0.25 < \text{Fraction Csp3} < 1$

FLEX (Flexibility): $0 < \text{Num. rotatable bonds} < 9$




Fig 2: Bioavailability Study for Gymnemic acids

To test the durability of a drug molecule, the Lipinski's rule of five is also used¹⁹. Therefore, for a bioactive compound to be considered an oral drug, this law is important²⁰. The basic information on bioactive compounds with their respective properties is provided in Fig: 2. The molecular docking *in silico* analysis revealed the significance of the structure-based drug design strategy for the production of novel drugs against the inhibition of the potential drug target. The enzyme's active site was docked with bioactive compounds (Oleic Acid) from methanolic leaf extract of Gymnemic acids (Figure

used to determine a compound's drug-likeness; in other words, it is very important for a compound to fulfill this rule in order to be administered orally¹⁹.

I).Physicochemical Properties for Gymnemic acids formula is $C_{43}H_{66}O_{14}$, (Fig :1) Molecular weight is 806.98 g/mol, Number of heavy atoms is 57, Number of atoms in heavy atoms is 0, Fraction Csp3 is 0.84, Num. rotatable bonds are 10, Num. H-bond acceptors are 14, Num. H-bond donors are 7, Molar Refractivity is 207.11 and TPSA is 229.74 \AA^2 . The Lipophilicity Log Po/w (iLOGP) is 2.28, Log Po/w (XLOGP3) is 0.86, Log Po/w (WLOGP) is 3.0311, Log Po/w (MLOGP) is 1.25, Log Po/w (SILICOS-IT) is 2.55 and Consensus Log Po/w is 2.59. The water Solubility for Log S (ESOL) is -6.62,

Solubility 1.96e-04 mg/ml; 2.43e-07 mol/l, Class is Poorly soluble, Log S (Ali) is -8.38, Solubility is 3.35e-06 mg/ml; 4.16e-09 mol/l, Class is poorly soluble, Log S (SILICOS-IT) is -2.85, Solubility is 1.15e+00 mg/ml; 1.43e-03 mol/l and Class is soluble. Toxicity of drugs is another extremely important problem, leading to a significant number of drug failures.

3.3 Boiled – Egg




Fig 3 Boiled – Egg plot of bioavailability of GYMNEMIC ACIDS

In Pharmacokinetics the GI absorption is Low, BBB permeate is No, P-gp substrate is Yes, CYP1A2 inhibitor is No, CYP2C19 inhibitor is No, CYP2C9 inhibitor is No, CYP2D6 inhibitor is No, CYP3A4 inhibitor is No and Log Kp (skin permeation) is -8.48 cm/s (Figure 3). In Drug likeness studies the Lipinski is No; 3 violations: MW>500, NorO>10, NHorOH>5, Ghose is No; 3 violations: MW>480, MR>130, #atoms>70, Veber is No; 1 violation: TPSA>140, Egan is No; 1 violation: TPSA>131.6, Muegge is No; 4 violations:

Author²⁰ published a review paper about a number of commercial prediction systems, including DEREK²¹, OncoLogic²², Hazard Expert, COMPACT²³, CASE/Multi-CASE²⁴ and TOPKAT²⁵ have developed QSAR models for the prediction of toxicity (Figure 2).

3.4 Target Classes – Top 15




Fig 4 Target Classes – Top 15

Higher value indicates lower hydrophilicity and, thus, poor absorption and permeation. A value indicates solubility; the lesser the value, the higher the solubility which would enhance the absorption^{31,32,33}. A lower molecular weight would again enhance the absorption rate and thus most of the drugs are tried to be kept at the lowest possible molecular weight. TPSA or *Topological Polar Surface Area* indicates the surface belonging to polar atoms in the compound (Figure 4). An increased TPSA is associated with diminished membrane permeability and the compounds with higher TPSA are better substrates for p-glycoprotein (responsible for drug efflux from cell). Thus comparing the compounds, lower TPSA is favourable for drug-like properties. It is also predicted that a molecule with better CNS penetration should have lower TPSA value^{34,35,36}.

4. CONCLUSION

Though *in silico* prediction of chemical toxicity has made a good progress in recent years, there are still some challenges and limitations to be improved. At first, data quality is still a big issue. Currently many toxicity data are obtained from high-throughput *in vitro* assays or *in vivo* tests on animals. The

7. REFERENCES

- Calixto JB. The role of natural products in modern drug discovery. *An Acad Bras Cienc.* 2019;91(Suppl 3):e20190105. doi: [10.1590/0001-3765201920190105](https://doi.org/10.1590/0001-3765201920190105), PMID 31166478.
- Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *J Nat Prod.* 2020;83(3):770-803. doi: [10.1021/acs.jnatprod.9b01285](https://doi.org/10.1021/acs.jnatprod.9b01285), PMID 32162523.
- Suwannarach N, Kumla J, Sujarit K, Pattananandecha T, Saenjum C, Lumyong S. Natural bioactive compounds from fungi as potential candidates for protease inhibitors and immunomodulators to apply for coronaviruses. *Molecules.* 2020;25(8):1800. doi: [10.3390/molecules25081800](https://doi.org/10.3390/molecules25081800), PMID 32295300.
- Teng YF, Xu L, Wei MY, Wang CY, Gu YC, Shao CL. Recent progresses in marine microbial-derived antiviral natural products. *Arch Pharm Res.* 2020;43(12):1215-29. doi: [10.1007/s12272-020-01286-3](https://doi.org/10.1007/s12272-020-01286-3), PMID 33222073.
- Mata R, Figueroa M, Navarrete A, Rivero-Cruz I. Chemistry and biology of selected Mexican medicinal plants. *Prog Chem Org Nat Prod.* 2019;108:1-142. doi: [10.1007/978-3-030-01099-7_1](https://doi.org/10.1007/978-3-030-01099-7_1), PMID 30924013.
- Wouters OJ, McKee M, Luyten J. Estimated Research and Development investment needed to bring a new medicine to market, 2009-2018. *JAMA.* 2020;323(9):844-53. doi: [10.1001/jama.2020.1166](https://doi.org/10.1001/jama.2020.1166), PMID 32125404.
- Ou-Yang SS, Lu JY, Kong XQ, Liang ZJ, Luo C, Jiang H. Computational drug discovery. *Acta Pharmacol Sin.* 2012;33(9):1131-40. doi: [10.1038/aps.2012.109](https://doi.org/10.1038/aps.2012.109), PMID 22922346.
- Pech-Puch D, Pérez-Povedano M, Lenis-Rojas OA, Rodríguez J, Jiménez C. Marine natural products from the Yucatan Peninsula. *Mar Drugs.* 2020;18(1):59. doi: [10.3390/md18010059](https://doi.org/10.3390/md18010059), PMID 31963310.
- Silva-Mares D, Rivas-Galindo VM, Salazar-Aranda R, Pérez-Lopez LA, Waksman De Torres N, Pérez-Meseguer J, Torres-Lopez E. Screening of north-east Mexico medicinal plants with activities against herpes simplex virus and human cancer cell line. *Nat Prod Res.* 2019;33(10):1531-4. doi: [10.1080/14786419.2017.1423300](https://doi.org/10.1080/14786419.2017.1423300), PMID 29334246.
- Kong R, Yang G, Xue R, Liu M, Wang F, Hu J, Guo X, Chang S. COVID-19 Docking Server: A meta server for docking small molecules, peptides and antibodies against potential targets of COVID-19. *Bioinformatics.* 2020;36(20):5109-11. doi: [10.1093/bioinformatics/btaa645](https://doi.org/10.1093/bioinformatics/btaa645), PMID 32692801.
- Miura T, Kamiya Y, Hina S, Kobayashi Y, Murayama N, Shimizu M, Yamazaki H. Metabolic profiles of coumarin in human plasma extrapolated from a rat data set with a simplified physiologically based pharmacokinetic model. *J Toxicol Sci.* 2020;45(11):695-700. doi: [10.2131/jts.45.695](https://doi.org/10.2131/jts.45.695), PMID 33132243.
- Azizah M, Pripdeevech P, Thongkongkaew T, Mahidol C, Ruchirawat S, Kittakoop P. UHPLC-ESI-QTOF-MS/MS-based molecular networking guided isolation and dereplication of antibacterial and antifungal constituents of *Ventilago denticulata*. *Antibiotics.* 2020;9(9):606. doi: [10.3390/antibiotics9090606](https://doi.org/10.3390/antibiotics9090606).
- Flores-Ocelotl MR, Rosas-Murrieta NH, Moreno DA, Vallejo-Ruiz V, Reyes-Leyva J, Domínguez F, Santos-López G. *Taraxacum officinale* and *Urtica dioica* extracts inhibit dengue virus serotype 2 replication in vitro. *BMC Complement Altern Med.* 2018;18(1):95. doi: [10.1186/s12906-018-2163-3](https://doi.org/10.1186/s12906-018-2163-3), PMID 29548293.
- Care C, Sornjai W, Jaratsittisin J, Hitakarun A, Wikan N, Triwitayakorn K, Smith DR. Discordant activity of kaempferol towards dengue virus and Japanese encephalitis virus. *Molecules.* 2020;25(5):1246. doi: [10.3390/molecules25051246](https://doi.org/10.3390/molecules25051246), PMID 32164193.
- Sharifi-Rad M, Roberts TH, Matthews KR, Bezerra CF, Morais-Braga MFB, Coutinho HDM, Sharopov F, Salehi B, Yousaf Z, Sharifi-Rad M, Del Mar Contreras M, Varoni EM, Verma DR, Iriti M, Sharifi-Rad J. Ethnobotany of the genus *Taraxacum*-Phytochemicals and antimicrobial activity. *Phytother Res.*

current study revealed the bioactive compounds (Gymnemic acid) for the inhibition of the enzyme leading to new discoveries of medicinal drugs based on plants. Computational analysis may be used for the drug development process as an efficient supporting tool. Computational simulations often give us, with high precision, a detailed performance. Therefore, in order to grow the drug discovery and development business, their participation is important.

5. AUTHOR CONTRIBUTION STATEMENT

Dr. Ramasamy Sujatha and Mrs.Dhanapal Indumathi conceptualized and discussed the methodology and results in the final manuscript and gathered the data with regard to this work., Dr. Palanisamy Shanmuga Sundaram analysed all the given data gathered. All authors discussed the methodology and results and contributed to the final manuscript.

6. CONFLICT OF INTEREST

Conflict of interest declared none

2018;32(11):2131-45. doi: [10.1002/ptr.6157](https://doi.org/10.1002/ptr.6157), PMID [30039597](https://pubmed.ncbi.nlm.nih.gov/30039597/).

16. Yeganegi M, Tabatabaei Yazdi F, Mortazavi SA, Asili J, Alizadeh Behbahani B, Beigbabaei A. *Equisetum telmateia* extracts: chemical compositions, antioxidant activity and antimicrobial effect on the growth of some pathogenic strain causing poisoning and infection. *Microb Pathog*. 2018;116:62-7. doi: [10.1016/j.micpath.2018.01.014](https://doi.org/10.1016/j.micpath.2018.01.014), PMID [29331369](https://pubmed.ncbi.nlm.nih.gov/29331369/).

17. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendum DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med*. 2020;26(10):1636-43. doi: [10.1038/s41591-020-1051-9](https://doi.org/10.1038/s41591-020-1051-9), PMID [32839624](https://pubmed.ncbi.nlm.nih.gov/32839624/).

18. Nisha CM, Kumar A, Nair P, Gupta N, Silakari C, Tripathi T, Kumar A. Molecular Docking and in silico ADMET study reveals Acylguanidine 7a as a potential inhibitor of beta secretase; 2016.

19. Zhao CN, Yao ZL, Yang D, Ke J, Wu QL, Li JK, Zhou XD. Chemical Constituents from *Fraxinus hupehensis* and Their Antifungal and Herbicidal Activities. *Biomolecules*. 2020;10(1):74. doi: [10.3390/biom10010074](https://doi.org/10.3390/biom10010074), PMID [31906487](https://pubmed.ncbi.nlm.nih.gov/31906487/).

20. Seregheti TMQ, Pinto APR, Gonçalves MDC, Antunes ADS, Almeida WADS, Machado RS, Silva JN, Ferreira PMP, Pessoa C, Santos VMRD, Nascimento AMD. Antiproliferative and photoprotective activities of the extracts and compounds from *Calea fruticosa*. *Braz J Med Biol Res*. 2020;53(9):e9375. doi: [10.1590/1414-431x20209375](https://doi.org/10.1590/1414-431x20209375), PMID [32696817](https://pubmed.ncbi.nlm.nih.gov/32696817/).

21. Basse MJ, Betzi S, Morelli X, Roche P. 2P2Idb v2: update of a structural database dedicated to orthosteric modulation of protein-protein interactions Database. 2016;10:1093. Doi: [10.1093/database/baw007](https://doi.org/10.1093/database/baw007)

22. Doak BC, Zheng J, Dobritzsch D, Kihlberg J. How beyond rule of 5 drugs and clinical candidates bind to their targets. *J Med Chem*. 2016;59(6):2312-27. doi: [10.1021/acs.jmedchem.5b01286](https://doi.org/10.1021/acs.jmedchem.5b01286), PMID [26457449](https://pubmed.ncbi.nlm.nih.gov/26457449/).

23. Green DR. A BH3 mimetic for killing cancer cells. *Cell*. 2016;165(7):1560. doi: [10.1016/j.cell.2016.05.080](https://doi.org/10.1016/j.cell.2016.05.080), PMID [27315468](https://pubmed.ncbi.nlm.nih.gov/27315468/).

24. Mignani S, Huber S, Tomás H, Rodrigues J, Majoral JP. Why and how have drug discovery strategies in pharma changed? What are the new mindsets? *Drug Discov Today*. 2016;21(2):239-49. doi: [10.1016/j.drudis.2015.09.007](https://doi.org/10.1016/j.drudis.2015.09.007), PMID [26376356](https://pubmed.ncbi.nlm.nih.gov/26376356/).

25. Villoutreix BO, Miteva MA. Discoidin domains as emerging therapeutic targets. *Trends Pharmacol Sci*. 2016;37(8):641-59. doi: [10.1016/j.tips.2016.06.003](https://doi.org/10.1016/j.tips.2016.06.003), PMID [27372370](https://pubmed.ncbi.nlm.nih.gov/27372370/).

26. Chatr-aryamontri A, Oughtred R, Boucher L, Rust J, Chang C, Kolas NK, O'Donnell L, Oster S, Theesfeld C, Sellam A, Stark C, Breitkreutz BJ, Dolinski K, Tyers M. The BioGRID interaction database: 2017 update. *Nucleic Acids Res*. 2017;45(D1):D369-79. doi: [10.1093/nar/gkw1102](https://doi.org/10.1093/nar/gkw1102), PMID [27980099](https://pubmed.ncbi.nlm.nih.gov/27980099/).

27. The UniProt Consortium. UniProt: the universal protein KnowledgeBase. *Nucleic Acids Res*. 2017;45(D1):D158-69. doi: [10.1093/nar/gkw1099](https://doi.org/10.1093/nar/gkw1099), PMID [27899622](https://pubmed.ncbi.nlm.nih.gov/27899622/).

28. Vora J, Patel S, Sinha S, Sharma S, Srivastava A, Chhabria M, Shrivastava N. Molecular docking, QSAR and ADMET based mining of natural compounds against prime targets of HIV. *J Biomol Struct Dyn*. 2019;37(1):131-46. doi: [10.1080/07391102.2017.1420489](https://doi.org/10.1080/07391102.2017.1420489), PMID [29268664](https://pubmed.ncbi.nlm.nih.gov/29268664/).

29. Dhiman V, Singh DK, Ladumor MK, Singh S. Characterization of stress degradation products of amodiaquine dihydrochloride by liquid chromatography with high-resolution mass spectrometry and prediction of their properties by using ADMET predictor™. *J Sep Sci*. 2017;40(23):4530-40. doi: [10.1002/jssc.201700904](https://doi.org/10.1002/jssc.201700904), PMID [28985017](https://pubmed.ncbi.nlm.nih.gov/28985017/).

30. Liu HK. Artemisinin, GABA signaling and cell reprogramming: when an old drug meets modern medicine. *Science Bulletin*. 2017;62(6):386-7. doi: [10.1016/j.scib.2017.02.006](https://doi.org/10.1016/j.scib.2017.02.006).

31. Zhang X, Zheng W, Wang T, Ren P, Wang F, Ma X, Wang J, Huang X. Danshen-Chuanxiong-Honghua Ameliorates cerebral impairment and improves spatial cognitive deficits after transient focal ischemia and identification of active compounds. *Front Pharmacol*. 2017;8:452. doi: [10.3389/fphar.2017.00452](https://doi.org/10.3389/fphar.2017.00452), PMID [28769792](https://pubmed.ncbi.nlm.nih.gov/28769792/).

32. Pathak A, Tanwar S, Kumar V, Banarjee BD. Present and future prospect of small molecule & related targeted therapy against human cancer. *Vivechan Int J Res*. 2018;9(1):36-49. PMID [30853755](https://pubmed.ncbi.nlm.nih.gov/30853755/).

33. Savvides SN, Elewaut D. Small-molecule inhibitors get pro-inflammatory TNF into shape. *Nat Rev Rheumatol*. 2020;16(4):189-90. doi: [10.1038/s41584-020-0388-2](https://doi.org/10.1038/s41584-020-0388-2), PMID [32060426](https://pubmed.ncbi.nlm.nih.gov/32060426/).

34. Lawson ADG, MacCoss M, Heer JP. Importance of rigidity in designing small molecule drugs to tackle protein-protein interactions (PPIs) through stabilization of desired conformers. *J Med Chem*. 2018;61(10):4283-9. doi: [10.1021/acs.jmedchem.7b01120](https://doi.org/10.1021/acs.jmedchem.7b01120), PMID [29140691](https://pubmed.ncbi.nlm.nih.gov/29140691/).

35. Fellmann C, Gowen BG, Lin PC, Doudna JA, Corn JE. Cornerstones of CRISPR-Cas in drug discovery and therapy. *Nat Rev Drug Discov*. 2017;16(2):89-100. doi: [10.1038/nrd.2016.238](https://doi.org/10.1038/nrd.2016.238), PMID [28008168](https://pubmed.ncbi.nlm.nih.gov/28008168/).

36. Stuart KA, Welsh K, Walker MC, Edrada-Ebel RA. Metabolomic tools used in marine natural product drug discovery. *Expert Opin Drug Discov*. 2020;15(4):499-522. doi: [10.1080/17460441.2020.1722636](https://doi.org/10.1080/17460441.2020.1722636), PMID [32026730](https://pubmed.ncbi.nlm.nih.gov/32026730/).